Advance safety and performance
Prevent additional surgeries from procedural complications1
*Occurrence of one of the following events between the time of implant and within 7 days following the procedure or by hospital discharge, whichever is later: all-cause death, ischemic stroke, systemic embolism, or device or procedure related events requiring open cardiac surgery or major endovascular intervention
WATCHMAN FLX data
The SURPASS analysis of the NCDR-LAAO Registry™ includes the largest number of commercial WATCHMAN FLX patients to date. This data reinforces the outstanding safety of WATCHMAN FLX with 0.37% major procedural adverse event rate within 7 days or hospital discharge and 98% procedural success rate in > 16,000 real-world NVAF patients.1
How we can help you and your program
Health Economics and Market Analysis
The Health Economics and Market Analysis (HEMA) team is dedicated to assisting WATCHMAN programs. See how HEMA can help with reimbursement education, patient access, program economics, and population health initiatives.
Healthcare Solutions team
Healthcare Solutions is a team of former hospital administrators who help LAAC programs identify- opportunities to accelerate program success and development. The Calibration Program identifies and tailors solutions to optimize LAAC programs.
HAWKEYE is a web-based patient workflow and reporting tool for your WATCHMAN program that is easily implemented into your care teams, and can provide immediate value to coordinators, implanters and administrators.
- Kar S, et al. Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device: Results From the PINNACLE FLX Trial. Circulation. 2021;143:1754-1762.